HIV Prevention: Considerations for Adolescents and Young Adults

During the adolescent and young adult years, people are faced with significant physical and developmental changes ...

APRIL 30, 2025

High Rates of PrEP Adherence and Persistence for F/TAF Patients

Patients who are naive to HIV PrEP and prescribed Descovy (Gilead) have a greater number of prescription ...

DECEMBER 19, 2022

Young Women in Africa Want Choices for HIV Protection

Adolescent girls and young women in Africa accepted both choices for preventing HIV infection: the monthly ...

FEBRUARY 15, 2022

Truvada for PrEP Led to Significant Declines in New HIV Infections

Thanks to PrEP, the United States has seen a decrease in HIV diagnoses.

JULY 24, 2018

FDA Expands Indication for Truvada for PrEP Among Adolescents

The FDA granted a new indication for Gilead's Truvada to reduce the risk for sexually acquired HIV-1 in at-risk ...

MAY 15, 2018

ViiV Healthcare Announces Phase 3 Study of Cabotegravir for PrEP in Women

ViiV Healthcare announced the start of a new phase 3 trial looking at cabotegravir for use as PrEP in women.

DECEMBER 1, 2017

Antivirals Among Medicaid’s Most Costly Drugs

HCV, HIV drugs top Medicaid drug spend, but some generics costly, too.

AUGUST 2, 2016